Abstract:Background Antiphospholipid syndrome (APS) is an autoimmune disease characterised mainly by arterial and/or venous thrombosis, recurrent pregnancy morbidity, with the presence of a variety of heterogeneous circulating antiphospholipid antibodies. However, there are a group of APS patients with persistently negative antiphospholipid antibodies. It is necessary to validate new specific antibodies to better recognition of these APS patients. Objectives To explore the clinical significance of non-criteria anti-phospholipid antibodies in a large cohort of Chinese patients with anti-phospholipid syndrome (APS). Methods Serum samples were obtained from 214 APS patients, 122 disease control including systemic lupus erythematosus, sjogren syndrome, ankylosing spondylitis, rheumatoid arthritis, osteoarthritis and 50 healthy control. Antiphosphatidylserine(IgA/IgG/IgM) (aPS), anti-phosphatidylethanolamine (IgA/IgG/IgM) (aPE), anti-prothrombin-antibodies (IgA/IgG/IgM) (aPT) , anti-annexin V-antibodies (IgA/IgG/IgM) (aAnxV), anti-phosoholipid-antibody(IgG/IgM)(aPL), anti-oxLDL antibody(IgG/IgM)(aoxLDL) were tested by ELISA kits(HUMAN Diagnostics Products, Germany) and IgG/IgM APhL were tested by ELISA(Louisville APL Diagnostic, USA). The Chi-square (χ2) test was used to examine the difference of frequencies of antibodies in APS patients and patients with other diseases. Spearman correlation analysis was performed to investigate the relationship between aPS/PT and other clinical/laboratory parameters. Results The prevalence of aPS IgG, aPS IgM, aPT, aPE, aAnxV, aPL, aoxLDL and IgG APhL, IgM APhL were 44.8%, 22.4%, 46.3%, 9.8%, 17.8%, 44.4%, 22.4%, 45.3% and 22.9%. The specificity of the antibodies were 82.6%, 95.3%, 96.0%, 99.4%, 95.3%, 92.4%, 87.2%, 95.3% and 94.8%. The highest positive predictive values of these antibodies were aPE. aPE, aPS IgM and APhL IgM were associated with thrombotic events and oxLDL, aPE, aPL, aPS IgG, aPS IgM, aPT, aoxLDL, APhL IgG and APHL IgM were correlated with anti-cardiolipin antibody(ACL). aPL, aPS IgG, aPS IgM, aPT, APhL IgG and APhL IgM were associated with β2-GP1 antibody. APhL IgG, APhL IgM and PS IgG were the highest prevalence in both ACL and lupus anticoagulant (LAC) negative patients. aPT has the highest prevalence in ACL and β2-GP1 negative patients and APhL IgG and aPS IgG were the highest two antibodies in LAC and β2-GP1 negative patients and aPT has the highest prevalence in seronegative APS patients. Conclusions Non-criteria aPLs have a good diagnostic value in APS and were associated with thrombotic events. References [1] Hughes GR, Khamashta MA (2003) Seronegative antiphospholipid syndrome. Ann Rheum Dis62:1127 [2] Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review.Rheumatology2015;54:2042–2050. [3] A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus2017;26(6):606–615. Acknowledgements We thank all patients and healthy donors whom took part in this study. Disclosure of Interest None declared

Anti–Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome

Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac‐1

NEUT-RI, a surrogate marker of NETosis is lower in patients with strong IgM antiphospholipid antibodies

Insight into antiphospholipid syndrome: the role and clinical utility of neutrophils extracellular traps formation

Neutrophils—Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Neutrophil glucose flux as a therapeutic target in antiphospholipid syndrome

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

Antiphospholipid antibody‐activated NETs exacerbate trophoblast and endothelial cell injury in obstetric antiphospholipid syndrome

Noncriteria antiphospholipid antibodies in antiphospholipid syndrome

Low ectonucleotidase activity and increased neutrophil-platelet aggregates in patients with antiphospholipid syndrome

Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression

Neutrophil extracellular trap formation in anti-neutrophil cytoplasmic antibody-associated and large-vessel vasculitis

An update on inflammation in antiphospholipid syndrome

Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients

AB0559 the Prevalence of Non-Criteria Anti-Phospholipid Antibodies in Anti-Phospholipid Syndrome

Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome

Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus

Neutrophil Extracellular Traps Profiles in Patients with Incident Systemic Lupus Erythematosus and Lupus Nephritis

T cell involvement in antiphospholipid syndrome

Non-criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: Diagnostic Value Added